Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone Quadrivalent in Children 6 to 35 Months of Age

Next Previous
Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone Quadrivalent in Children 6 to 35 Months of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2282512A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GSK

Most Recent Events

  • 21 Nov 2016 According to a GSK media release, based on the data from this and other three studies, the US FDA approved supplemental Biologics License Application for FluLaval Quadrivalent (Influenza Vaccine) for use in children of 6 months and older.
  • 11 Apr 2016 Treatment arms changed from 4 to 2.
  • 02 Feb 2016 According to a GlaxoSmithKline media release, the results of this study will be presented at the annual meeting of Pediatric Academic Societies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top